ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO419

Efficient and Programmable Particle Delivery for Genome Editing in Human Kidney Organoids

Session Information

Category: Development, Stem Cells, and Regenerative Medicine

  • 600 Development, Stem Cells, and Regenerative Medicine

Authors

  • Vo, Nicole, University of Washington, Seattle, Washington, United States
  • Freedman, Benjamin S., University of Washington, Seattle, Washington, United States
Background

Kidney organoids are complex structures that resemble nephrons and can be used to develop gene therapy approaches. Gene editing in organoids, much like in tissues, has great potential but currently suffers from inefficiency and lack of specificity. There is a critical need for the development of methods for efficient and precise genome editing.

Methods

We developed CaSh (Calcium Shock), a method that improves transfection and transduction, and CaSh-Pro, a programmable version that targets specific cell types. To enable better detection of genome editing events, we developed a fluorescence-on (tdTomato) reporter system in human iPS cells. Intact kidney organoids were transfected with CRISPR ribonucleoprotein (RNP) complexes. To improve delivery, identified molecular targeting agents (MTAs) specifically recognizing podocytes, proximal tubules, or endothelial cells in live imaging assays, and tethered these to Cas9. Genome editing events or adeno-associated virus (AAV) transduction were detected by changes in fluorescence in specific cell types.

Results

CaSh dramatically improved genome editing by CRISPR-Cas9 ribonucleoprotein from ~ 2% in organoids without CaSh to 15% with CaSh. CaSh-Pro, which incorporates specific MTAs, resulted in substantially enhanced editing in the targeted cell types of podocytes (~12%) (Figure 1) or tubules (~5%), as detected by tdTomato co-localization with a specific marker, relative to negative controls including untreated, no MTA, or generic IgG. Finally, CaSh improved transduction of AAV8 encoding a red fluorescent reporter protein into proximal tubular epithelial cells, resulting in ~15% efficiency at 1 x 105 genome copies (gc)/cell, compared to negative controls.

Conclusion

CaSh and CaSh-Pro provide versatile protocols for biological discovery, therapeutics development, and genome editing. Our innovative method improves specificity and efficiency enabling a wide variety of potential applications such as testing gene therapies in specific cell types as a surrogate for tissues. Gene editing can be achieved in a clinically effective range (> 10%) and in specific cell types, enabling future studies of phenotypic rescue in human models.

Funding

  • NIDDK Support